Skip to main content.

Krishna Reddy, M.D., Ph.D.

Krishna Reddy portrait
Associate Professor, Radiation Oncology
kreddy@kumc.edu

Professional Background

Krishna Reddy, MD, PhD, recently joined the cancer center as an associate professor in the Department of Radiation Oncology. Dr. Reddy is a graduate of the University of Texas-Houston medical school and completed his PhD in cancer biology at the M.D. Anderson Cancer Center. He completed his residency in radiation oncology at the University of Colorado in 2013. Prior to joining KU, he was a faculty member in the radiation oncology department at the University of Toledo medical center, where he served as chairman of the cancer committee and helped build the cancer program.

Dr. Reddy is passionate about providing compassionate, patient-centered, and multidisciplinary oncology care using the best, state-of-the-art treatment techniques. He specializes in the treatment of a variety of cancers, including breast, lung, central nervous system, head and neck, genitourinary and gastrointestinal cancers. He has extensive experience in stereotactic radiosurgery/ stereotactic body radiation treatment (SRS/SABR), including the use of these highly targeted approaches in the care of patients with oligometastatic/metastatic cancer.

Education and Training
  • MD, Radiation Oncology, University of Texas Medical School at Houston, Houston, Texas
  • PhD, Cancer Biology, University of Texas Graduate School of Biomedical Sciences/M.D. Anderson Cancer Center, Houston, Texas
  • BS, Microbiology, University of Texas at El Paso, El Paso, Texas
  • Other, Radiation Oncology, University of Colorado, Aurora, Colorado
  • Residency, Radiation Oncology, University of Colorado, Aurora, Colorado
  • Internship, Lyndon B. Johnson General Hospital, Houston, Texas

Research

Overview

As a physician-scientist, he is also involved in designing and leading clinical trials at the KU cancer center. His research interests include: the use of shorter course (hypo-fractionated) radiation treatment schedules for various cancers (including locally advanced lung cancer), application of state-of-the-art radiotherapy techniques (SRS/SBRT) in the treatment of metastatic and oligometastatic cancer, and the combination/integration of novel targeted systemic therapies with radiation treatment (including SRS/SBRT).